Bb5a31f81ClaimMore than 20 pharmaceutical companies reached agreements with the Trump administration pledging not to charge significantly higher drug prices in the United States than in other nationsAgreeDisagree
Bb5a31f81ClaimBayer co-markets a blood-thinner medication with Johnson & Johnson that faces generic market competitionAgreeDisagree
Bb5a31f81ClaimBayer's drug San Arbo is designed to prevent repeat strokes without significantly increasing a patient's bleeding risk compared to standard blood thinnersAgreeDisagree
Bb5a31f81ClaimThe United States Food and Drug Administration approved Bayer's blood thinner San Arbo to decrease the risk of dangerous internal bleedingAgreeDisagree
Bb5a31f81ClaimMarket research firm GlobalData recorded a 27% decline in new European pharmaceutical launches over a 17-month periodAgreeDisagree
Bb5a31f81ClaimUnder Attorney General Ken Paxton, the Texas Attorney General's office filed legal challenges against DACA and the sale of mifepristoneAgreeDisagree
Bb5a31f81ClaimAn Environmental Protection Agency assessment on glyphosate safety was discarded in court after evidence showed chemical company Bayer ghostwrote research sectionsAgreeDisagree
Bb5a31f81ClaimDepartment of Justice attorney Sarah Harris, previously employed at Bayer's primary law firm, drafted the brief supporting glyphosate liability protection before the Supreme CourtAgreeDisagree
Bb5a31f81ClaimThe Food and Drug Administration Center for Biologics Evaluation and Research vaccine division was led by a former head of vaccine development at MerckAgreeDisagree
Bb5a31f81ClaimThe federal standard for 7-hydroxymitragynine in kratom products was initially recommended at a concentration cap of 0.05 percentAgreeDisagree
Bb5a31f81ClaimFood and Drug Administration Commissioner Marty Makary was dismissed from office after resisting efforts to ease approval standards for fruit-flavored e-cigarettesAgreeDisagree
Bb5a31f81ClaimThe concentration allowance for the opioid alkaloid 7-hydroxymitragynine in retail kratom products was raised twentyfold above initial recommendationsAgreeDisagree
Bb5a31f81ClaimFederal regulations require safety studies demonstrating a lack of harm to minors prior to Food and Drug Administration approval of vaping productsAgreeDisagree
Bb5a31f81ClaimThe American Heart Association filed a lawsuit against the Food and Drug Administration challenging relaxed standards on fruit-flavored vaping productsAgreeDisagree
Bb5a31f81ClaimThe United States Department of Health and Human Services compounding peptide policy includes requirements regarding registered manufacturing facilities, certificates of analysis, and labelingAgreeDisagree
Bb5a31f81ClaimThe United States Department of Health and Human Services announced an enforcement policy covering six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500AgreeDisagree
Bb5a31f81ClaimThe United States Department of Health and Human Services compounding peptide policy restricts the combination of multiple active peptides into a single compounded productAgreeDisagree
Bb5a31f81ClaimUnder specific conditions, the United States Department of Health and Human Services does not intend to take enforcement action against certain peptide compounders while an FDA formal evaluation process continuesAgreeDisagree
Bb5a31f81ClaimThe ICON study published in the journal Chest demonstrated a greater than 50% reduction in mortality among hospitalized COVID-19 patients treated with ivermectinAgreeDisagree
Bb5a31f81ClaimThe Federal Trade Commission sued Nate Jones and Xlear Corporation over marketing and studies of nasal sprays and gargles against SARS-CoV-2AgreeDisagree